71 related articles for article (PubMed ID: 9790546)
1. Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
Moinpour CM; Savage MJ; Troxel A; Lovato LC; Eisenberger M; Veith RW; Higgins B; Skeel R; Yee M; Blumenstein BA; Crawford ED; Meyskens FL
J Natl Cancer Inst; 1998 Oct; 90(20):1537-44. PubMed ID: 9790546
[TBL] [Abstract][Full Text] [Related]
2. [Drastic changes in the treatment of metastatic prostate cancer].
Thellenberg Karlsson C; Ståhl O
Lakartidningen; 2024 Apr; 121():. PubMed ID: 38651316
[TBL] [Abstract][Full Text] [Related]
3. Changes in Quality of Life and Sexual Function After Luteinizing Hormone-Releasing Hormone (LHRH) Agonists and Orchiectomy in Men With Metastatic Prostate Cancer: Results From a Randomized Trial.
Dissing N; Fode M; Østergren P; Sønksen J
Cureus; 2024 Mar; 16(3):e55934. PubMed ID: 38601370
[TBL] [Abstract][Full Text] [Related]
4. Subcapsular orchiectomy in the primary therapy of patients with bone metastasis in advanced prostate cancer: an anachronistic intervention?
Rud O; Peter J; Kheyri R; Gilfrich C; Ahmed AM; Boeckmann W; Fabricius PG; May M
Adv Urol; 2012; 2012():190624. PubMed ID: 21922019
[TBL] [Abstract][Full Text] [Related]
5. Quantifying bias due to missing data in quality of life surveys of advanced-stage cancer patients.
Haug N; Jänicke M; Kasenda B; Marschner N; Frank M
Qual Life Res; 2024 Apr; 33(4):1085-1094. PubMed ID: 38240915
[TBL] [Abstract][Full Text] [Related]
6. Quality of life issues in patients with bone metastases: A systematic review.
Rajeswaran T; Wong HCY; Zhang E; Kennedy SKF; Gojsevic M; Soliman H; Vassiliou V; Rades D; Bonomo P; Lee SF; Chan AW; Rembielak A; Oldenburger E; Maranzano E; Pergolizzi S; Finkelstein JA; Larouche J; Zhang N; Zhang X; Marta GN; Yee AJM; Yu S; van der Velden JM; van der Linden YM; Chow E;
Support Care Cancer; 2023 Dec; 32(1):18. PubMed ID: 38091116
[TBL] [Abstract][Full Text] [Related]
7. Quality of life and mortality in the general population: a systematic review and meta-analysis.
Phyo AZZ; Freak-Poli R; Craig H; Gasevic D; Stocks NP; Gonzalez-Chica DA; Ryan J
BMC Public Health; 2020 Nov; 20(1):1596. PubMed ID: 33153441
[TBL] [Abstract][Full Text] [Related]
8. A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).
Hasan H; Deek MP; Phillips R; Hobbs RF; Malek R; Radwan N; Kiess AP; Dipasquale S; Huang J; Caldwell T; Leitzel J; Wendler D; Wang H; Thompson E; Powell J; Dudley S; Deville C; Greco SC; Song DY; DeWeese TL; Gorin MA; Rowe SP; Denmeade S; Markowski M; Antonarakis ES; Carducci MA; Eisenberger MA; Pomper MG; Pienta KJ; Paller CJ; Tran PT
BMC Cancer; 2020 Jun; 20(1):492. PubMed ID: 32487038
[TBL] [Abstract][Full Text] [Related]
9. Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy.
Park HS; Shin HB; Woo SH; Jeon SH; Lee SH; Kang SH; Shim JS; Shin DW; Park J
World J Urol; 2020 Apr; 38(4):971-979. PubMed ID: 31187203
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Physical Function Measures in Cancer Clinical Trials.
Atkinson TM; Stover AM; Storfer DF; Saracino RM; D'Agostino TA; Pergolizzi D; Matsoukas K; Li Y; Basch E
Epidemiol Rev; 2017 Jan; 39(1):59-70. PubMed ID: 28453627
[TBL] [Abstract][Full Text] [Related]
11. The impact of chronic disease on orphans' quality of life living in extended social care services: a cross sectional analysis.
Alonazi WB
Health Qual Life Outcomes; 2016 Apr; 14():55. PubMed ID: 27044384
[TBL] [Abstract][Full Text] [Related]
12. Hormonal therapy in metastatic prostate cancer: current perspectives and controversies.
Garg M; Singh V; Kumar M; Sankhwar SN
Oncol Rev; 2013 Apr; 7(1):e6. PubMed ID: 25992227
[TBL] [Abstract][Full Text] [Related]
13. Enhancing nurse contributions to SWOG clinical trials.
Hansen LK; Moinpour CM; Ermete RB
Semin Oncol Nurs; 2014 Feb; 30(1):26-31. PubMed ID: 24559777
[TBL] [Abstract][Full Text] [Related]
14. The association of retinoic acid receptor beta2(RARβ2) methylation status and prostate cancer risk: a systematic review and meta-analysis.
Gao T; He B; Pan Y; Li R; Xu Y; Chen L; Nie Z; Gu L; Wang S
PLoS One; 2013; 8(5):e62950. PubMed ID: 23675444
[TBL] [Abstract][Full Text] [Related]
15. Intermittent versus continuous androgen deprivation in prostate cancer.
Hussain M; Tangen CM; Berry DL; Higano CS; Crawford ED; Liu G; Wilding G; Prescott S; Kanaga Sundaram S; Small EJ; Dawson NA; Donnelly BJ; Venner PM; Vaishampayan UN; Schellhammer PF; Quinn DI; Raghavan D; Ely B; Moinpour CM; Vogelzang NJ; Thompson IM
N Engl J Med; 2013 Apr; 368(14):1314-25. PubMed ID: 23550669
[TBL] [Abstract][Full Text] [Related]
16. Treating prostate cancer in elderly men: how does aging affect the outcome?
Shelke AR; Mohile SG
Curr Treat Options Oncol; 2011 Sep; 12(3):263-75. PubMed ID: 21656153
[TBL] [Abstract][Full Text] [Related]
17. Long-term quality of life after radical prostatectomy in wives of men in the postoperative adjuvant androgen deprivation trial.
Sterba KR; Swartz RJ; Basen-Engquist K; Black PC; Pettaway CA
Support Care Cancer; 2011 Aug; 19(8):1117-24. PubMed ID: 20499107
[TBL] [Abstract][Full Text] [Related]
18. Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment.
Casas F; Borràs JM; Ferrer F; Guanyabens N; Gutiérrez del Pozo R; León C; López Torrecilla J; Mellado B; Morote J; Puig M; Ribal MJ; Ruscalleda C; Serra A; Valls V; Zapatero A
Clin Transl Oncol; 2010 May; 12(5):346-55. PubMed ID: 20466619
[TBL] [Abstract][Full Text] [Related]
19. Management of complications of androgen deprivation therapy in the older man.
Mohile SG; Mustian K; Bylow K; Hall W; Dale W
Crit Rev Oncol Hematol; 2009 Jun; 70(3):235-55. PubMed ID: 18952456
[TBL] [Abstract][Full Text] [Related]
20. Maximal androgen blockade for the treatment of metastatic prostate cancer--a systematic review.
Lukka H; Waldron T; Klotz L; Winquist E; Trachtenberg J; ;
Curr Oncol; 2006 Jun; 13(3):81-93. PubMed ID: 17576447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
